Status:
TERMINATED
Allogeneic Hematopoietic Stem Cell Transplantation in Pancreatic Adenocarcinoma
Lead Sponsor:
Karolinska Institutet
Collaborating Sponsors:
Karolinska University Hospital
Conditions:
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Aim: To study the antitumour effect of reduced intensity conditioning (RIC) with allogeneic stem cell transplantation (HSCT) in patients with pancreatic adenocarcinoma after radical resection of the ...
Detailed Description
Background Cancer of the pancreas is one of the most common cancer forms in Sweden. Nine-hundred persons receive this diagnosis every year. The 5-year survival is very low, between 5 and 15%, even in ...
Eligibility Criteria
Inclusion
- Patients with pancreatic adenocarcinoma who have undergone curative surgery ad modum Whipple with radical resection of the tumor, R0 or R1.
Exclusion
- Pancreatic adenocarcinoma with metastasis or non-radical resection.
- Recurrence of the malignancy after curative surgery and adjuvant chemotherapy.
- Age above 70 years.
- Severe heart disease, liver disease, impaired renal function or other organ failure or underlying diseases that would exclude the patient from undergoing hematopoietic stem cell transplantation.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2017
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02207985
Start Date
January 1 2007
End Date
June 1 2017
Last Update
July 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for allogeneic stem cell transplantation, Karolinska University hospital
Stockholm, Sweden, 141 86